| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis L Kappos, EW Radue, P O'Connor, C Polman, R Hohlfeld, P Calabresi, ... New England Journal of Medicine 362 (5), 387-401, 2010 | 3319 | 2010 |
| Ocrelizumab versus placebo in primary progressive multiple sclerosis X Montalban, SL Hauser, L Kappos, DL Arnold, A Bar-Or, G Comi, ... New england journal of medicine 376 (3), 209-220, 2017 | 2100 | 2017 |
| Oral fingolimod (FTY720) for relapsing multiple sclerosis L Kappos, J Antel, G Comi, X Montalban, P O'Connor, CH Polman, T Haas, ... New England Journal of Medicine 355 (11), 1124-1140, 2006 | 1341 | 2006 |
| Clinical relevance of brain volume measures in multiple sclerosis N De Stefano, L Airas, N Grigoriadis, HP Mattle, J O’Riordan, ... CNS drugs 28, 147-156, 2014 | 394 | 2014 |
| Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open … R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ... The Lancet Neurology 17 (5), 405-415, 2018 | 367 | 2018 |
| 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis M Soilu-Hänninen, L Airas, I Mononen, A Heikkilä, M Viljanen, ... Multiple Sclerosis Journal 11 (3), 266-271, 2005 | 336 | 2005 |
| CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis JH Mills, LF Thompson, C Mueller, AT Waickman, S Jalkanen, J Niemela, ... Proceedings of the National Academy of Sciences 105 (27), 9325-9330, 2008 | 237 | 2008 |
| Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study P O'connor, G Comi, X Montalban, J Antel, EW Radue, A De Vera, ... Neurology 72 (1), 73-79, 2009 | 232 | 2009 |
| Differential regulation and function of CD73, a glycosyl-phosphatidylinositol–linked 70-kD adhesion molecule, on lymphocytes and endothelial cells L Airas, J Niemelä, M Salmi, T Puurunen, DJ Smith, S Jalkanen The Journal of cell biology 136 (2), 421-431, 1997 | 229 | 1997 |
| Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study V Devonshire, E Havrdova, EW Radue, P O'Connor, L Zhang-Auberson, ... The Lancet Neurology 11 (5), 420-428, 2012 | 217 | 2012 |
| Smouldering multiple sclerosis: the ‘real MS’ G Giovannoni, V Popescu, J Wuerfel, K Hellwig, E Iacobaeus, MB Jensen, ... Therapeutic advances in neurological disorders 15, 17562864211066751, 2022 | 201 | 2022 |
| Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice JCC de Sa, L Airas, E Bartholome, N Grigoriadis, H Mattle, ... Therapeutic advances in neurological disorders 4 (3), 139-168, 2011 | 200 | 2011 |
| In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand 11C-PK11195 E Rissanen, J Tuisku, J Rokka, T Paavilainen, R Parkkola, JO Rinne, ... Journal of Nuclear Medicine 55 (6), 939-944, 2014 | 191 | 2014 |
| Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results G Comi, P O'Connor, X Montalban, J Antel, EW Radue, G Karlsson, ... Multiple Sclerosis Journal 16 (2), 197-207, 2010 | 186 | 2010 |
| CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73. L Airas, J Hellman, M Salmi, P Bono, T Puurunen, DJ Smith, S Jalkanen The Journal of experimental medicine 182 (5), 1603-1608, 1995 | 185 | 1995 |
| Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta M Saraste, H Irjala, L Airas Neurological Sciences 28, 121-126, 2007 | 176 | 2007 |
| Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180 AM Dickens, S Vainio, P Marjamäki, J Johansson, P Lehtiniemi, J Rokka, ... Journal of nuclear medicine 55 (3), 466-472, 2014 | 175 | 2014 |
| Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity H Högel, E Rissanen, C Barro, M Matilainen, M Nylund, J Kuhle, L Airas Multiple Sclerosis Journal 26 (2), 210-219, 2020 | 157 | 2020 |
| Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells Finnish Multiple Sclerosis and Pregnancy Study Group Airas L laura. airas ... Clinical & Experimental Immunology 151 (2), 235-243, 2008 | 135 | 2008 |
| Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP) H Butzkueven, L Kappos, H Wiendl, M Trojano, T Spelman, I Chang, ... Journal of Neurology, Neurosurgery & Psychiatry 91 (6), 660-668, 2020 | 133 | 2020 |
